JP2025111424A5 - - Google Patents

Info

Publication number
JP2025111424A5
JP2025111424A5 JP2025043874A JP2025043874A JP2025111424A5 JP 2025111424 A5 JP2025111424 A5 JP 2025111424A5 JP 2025043874 A JP2025043874 A JP 2025043874A JP 2025043874 A JP2025043874 A JP 2025043874A JP 2025111424 A5 JP2025111424 A5 JP 2025111424A5
Authority
JP
Japan
Prior art keywords
aqueous
solution
pharmaceutical
dota
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025043874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025111424A (ja
Filing date
Publication date
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Priority claimed from JP2021504167A external-priority patent/JP7402218B2/ja
Application filed filed Critical
Publication of JP2025111424A publication Critical patent/JP2025111424A/ja
Publication of JP2025111424A5 publication Critical patent/JP2025111424A5/ja
Pending legal-status Critical Current

Links

JP2025043874A 2018-07-25 2025-03-18 安定な濃厚放射性核種錯体溶液 Pending JP2025111424A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
IBPCT/IB2018/055575 2018-07-25
US16/045,484 2018-07-25
JP2021504167A JP7402218B2 (ja) 2018-07-25 2018-09-25 安定な濃厚放射性核種錯体溶液
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions
JP2023085193A JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023085193A Division JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Publications (2)

Publication Number Publication Date
JP2025111424A JP2025111424A (ja) 2025-07-30
JP2025111424A5 true JP2025111424A5 (cg-RX-API-DMAC7.html) 2025-10-23

Family

ID=63794577

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021504167A Active JP7402218B2 (ja) 2018-07-25 2018-09-25 安定な濃厚放射性核種錯体溶液
JP2023085193A Active JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液
JP2025043874A Pending JP2025111424A (ja) 2018-07-25 2025-03-18 安定な濃厚放射性核種錯体溶液

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021504167A Active JP7402218B2 (ja) 2018-07-25 2018-09-25 安定な濃厚放射性核種錯体溶液
JP2023085193A Active JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Country Status (23)

Country Link
EP (7) EP4545100B1 (cg-RX-API-DMAC7.html)
JP (3) JP7402218B2 (cg-RX-API-DMAC7.html)
KR (4) KR102865113B1 (cg-RX-API-DMAC7.html)
CN (5) CN112584875A (cg-RX-API-DMAC7.html)
AU (7) AU2018433575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001148A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153630A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000506A2 (cg-RX-API-DMAC7.html)
DE (3) DE202018007006U1 (cg-RX-API-DMAC7.html)
DK (7) DK4640241T3 (cg-RX-API-DMAC7.html)
ES (6) ES3064434T3 (cg-RX-API-DMAC7.html)
FI (7) FI4545101T3 (cg-RX-API-DMAC7.html)
HR (6) HRP20260222T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072720T2 (cg-RX-API-DMAC7.html)
IL (5) IL280314B1 (cg-RX-API-DMAC7.html)
LT (7) LT4541381T (cg-RX-API-DMAC7.html)
MX (2) MX2021000805A (cg-RX-API-DMAC7.html)
PL (6) PL4545100T3 (cg-RX-API-DMAC7.html)
PT (7) PT4541381T (cg-RX-API-DMAC7.html)
RS (7) RS67729B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100645XA (cg-RX-API-DMAC7.html)
SI (6) SI4541381T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020021322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
US20250032652A1 (en) * 2021-11-30 2025-01-30 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CA3235923A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
US20260102526A1 (en) * 2024-06-27 2026-04-16 Curium Us Llc 177lutetium-dota-tate formulations
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Similar Documents

Publication Publication Date Title
CN102458396B (zh) 使用抗坏血酸稳定化放射性药物组合物
JP2023552180A5 (cg-RX-API-DMAC7.html)
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
ES2355100T3 (es) Composiciones mejoradas de complejos de radiometal.
JP2023117417A5 (cg-RX-API-DMAC7.html)
JP2025506001A5 (cg-RX-API-DMAC7.html)
CA2188133C (en) Tin-117m-containing radiotherapeutic agents
AU2024227297A1 (en) Methods for radiolabeling PSMA binding ligands and their kits
JP4345954B2 (ja) 放射性医薬品の安定化剤
RU2846977C1 (ru) Способы мечения радиоактивными изотопами psma-связывающих лигандов и наборы для их осуществления
AU2010237040B9 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
RU2021117127A (ru) Радиофармацевтическое лекарственное средство - фармацевтическая субстанция общей структуры R-X, произведенная для реализации и включенная в государственный реестр лекарственных средств согласно законодательству страны планируемой реализации, пригодная для производства или изготовления радиофармацевтических лекарственных препаратов
HK1245645B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
RU2021101166A (ru) Стабильные концентрированные растворы комплексов радионуклидов
HK1167344B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid